AR053990A1 - Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion. - Google Patents

Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.

Info

Publication number
AR053990A1
AR053990A1 ARP050105253A ARP050105253A AR053990A1 AR 053990 A1 AR053990 A1 AR 053990A1 AR P050105253 A ARP050105253 A AR P050105253A AR P050105253 A ARP050105253 A AR P050105253A AR 053990 A1 AR053990 A1 AR 053990A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
pirazolpiridina
inhibitor
compact
factor
Prior art date
Application number
ARP050105253A
Other languages
English (en)
Spanish (es)
Inventor
Michael J Orwat
Mary F Malley
Roxana F Schlam
Steven R Fabian
Bing-Shiou Yang
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR053990A1 publication Critical patent/AR053990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP050105253A 2004-12-15 2005-12-14 Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion. AR053990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR053990A1 true AR053990A1 (es) 2007-05-30

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105253A AR053990A1 (es) 2004-12-15 2005-12-14 Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.

Country Status (15)

Country Link
US (2) US7371864B2 (https=)
EP (1) EP1828187A2 (https=)
JP (1) JP2008524228A (https=)
KR (1) KR20070087606A (https=)
AR (1) AR053990A1 (https=)
AU (1) AU2005317158A1 (https=)
BR (1) BRPI0519331A2 (https=)
CA (1) CA2589886A1 (https=)
IL (1) IL183825A0 (https=)
MX (1) MX2007006919A (https=)
NO (1) NO20072666L (https=)
PE (1) PE20060739A1 (https=)
RU (1) RU2007126770A (https=)
TW (1) TW200634011A (https=)
WO (1) WO2006065853A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636756B2 (en) 2008-05-27 2019-11-20 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
EP2401396B1 (en) 2009-02-26 2016-11-23 Dako Denmark A/S Methods for performing a stringent wash step in hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (en) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridization compositions and methods
AR116951A1 (es) 2018-11-02 2021-06-30 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2461202C (en) * 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7388096B2 (en) * 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones

Also Published As

Publication number Publication date
KR20070087606A (ko) 2007-08-28
WO2006065853A3 (en) 2006-08-24
NO20072666L (no) 2007-09-07
AU2005317158A1 (en) 2006-06-22
CA2589886A1 (en) 2006-06-22
MX2007006919A (es) 2007-06-26
JP2008524228A (ja) 2008-07-10
BRPI0519331A2 (pt) 2009-01-20
RU2007126770A (ru) 2009-01-27
PE20060739A1 (es) 2006-08-16
US7371864B2 (en) 2008-05-13
IL183825A0 (en) 2007-09-20
EP1828187A2 (en) 2007-09-05
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
US20080188517A1 (en) 2008-08-07
WO2006065853A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
DK1894564T3 (da) Anvendelse af en IBAT inhibitor til behandling eller profylakse af konstipation
PE20130591A1 (es) Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
UY28513A1 (es) Nuevos compuestos
DK1644398T3 (da) Specifik glucocorticosteroidforbindelse med antiinflammatorisk aktivitet
JP2005526058A5 (https=)
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
DK1613335T3 (da) Blodkardannelse induceret af perivaskulære mesenchymale precursorceller
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
MX2009010761A (es) Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
EA200300348A1 (ru) Спирогетероциклические нитрилы, пригодные для применения в качестве обратимо действующих ингибиторов цистеиновых протеаз
PE20090742A1 (es) Formas solidas de (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)-pirimidin-4-il)fenil)propanoato de etilo y metodos para su uso
TWI350300B (en) Azo compounds and polarizing membranes and plates containing the same
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
AR053990A1 (es) Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa. composiciones farmaceuticas y procesos de obtencion.
SE0203304D0 (sv) Novel Coumpounds
BRPI0509154A (pt) composição quìmica e usos
EP1740183B8 (en) Novel use for pde5 inhibitors
AR046131A1 (es) Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona
UY31866A (es) Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones
CL2008001043A1 (es) Forma amorfa y cristalina de la oxima de la e-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)-etanona; composicion farmaceutica; y uso para tratar, controlar o prevenir una enfermedad o un trastorno autoinmune o inflamatorio.
ATE366714T1 (de) Verwendung von mehrfach modifiziertem zeolith in der biogasgewinnung
MX2007011493A (es) Modalidades antiinflamatorias.
ATE412985T1 (de) Verbesserungen in der verwendung von brennstoff in elektrochemischen brennstoffzellen

Legal Events

Date Code Title Description
FB Suspension of granting procedure